SCHEMBL1743346

SCHEMBL1743346

CC#CCCC#CC(C)(C)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8960613 0.77
SCHEMBL8847277 0.71 PTPN7 (0.40)
SCHEMBL8960458 0.68
SCHEMBL25005935 0.68
SCHEMBL233379 0.67
SCHEMBL8388785 0.65
SCHEMBL1961299 0.65
SCHEMBL28162082 0.65 LMNA (0.32)
SCHEMBL8960922 0.65
SCHEMBL1897706 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170216282-A1 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders GALDERMA LABORATORIES INC 2017-08-03 US disclosed
US-20150202202-A1 COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS Galderma Laboratories, L.P. (US) 2015-07-23 US disclosed
US-8993571-B2 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders Galderma Laboratories, L.P. (US) 2015-03-31 US disclosed
EP-2815748-A1 Compounds, formulations, and methods for treating or preventing rosacea Galderma Pharma S.A. (CH) 2014-12-24 EP disclosed
US-8859551-B2 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders GALDERMA LABORATORIES INC. (US) 2014-10-14 US disclosed
US-8557817-B2 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders GALDERMA LABORATORIES INC. (US) 2013-10-15 US disclosed
US-20130172358-A1 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders GALDERMA LABORATORIES INC. (US) 2013-07-04 US disclosed
US-20130172359-A1 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders GALDERMA LABORATORIES INC. (US) 2013-07-04 US disclosed
EP-1761266-B1 COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS GALDERMA PHARMA SA (CH) 2013-05-08 EP disclosed
US-20120277241-A1 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders GALDERMA LABORATORIES, INC. (US) 2012-11-01 US disclosed
EP-2481412-A1 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders Galderma Pharma S.A. (CH) 2012-08-01 EP disclosed
EP-2388007-A1 Compounds, formulations, and methods for treating or preventing rosacea Galderma Pharma S.A. (CH) 2011-11-23 EP disclosed
EP-1631293-B1 COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING ROSACEA GALDERMA PHARMA SA (CH) 2011-10-26 EP disclosed
US-8038451-B2 Multi-board printed circuit assembly having aligned connectors HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2011-10-18 US disclosed
US-7439241-B2 Compounds, formulations, and methods for treating or preventing rosacea GALDERMA LABORATORIES, INC. (US) 2008-10-21 US disclosed
US-20060171974-A1 Compounds, formulations, and methods for treating or preventing rosacea GALDERMA LABORATORIES INC. 2006-08-03 US disclosed
US-20050276830-A1 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders GALDERMA LABORATORIES INC. 2005-12-15 US disclosed
US-20040242588-A1 Compounds, formulations, and methods for treating or preventing rosacea Galderma Holding SA (CH) 2004-12-02 US disclosed
US-6369052-B1 REVERSE NEURONAL DYSFUNCTION; ALZHEIMER'S; PARKINSON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; STROKES; SPINAL-CORD AND PERIPHERAL NERVE INJURIES; TRANSDERMAL PATCH. GEORGETOWN UNIVERSITY 2002-04-09 US disclosed